Critical Limb Ischemia
Conditions
Brief summary
Designed as a single center, two-part, double-blind, placebo-controlled, randomized study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RJX in healthy participants.
Detailed description
Part 1 is designed as a Single Ascending Dose (SAD) escalation study with 6 cohorts. Participants will undertake a screening visit between Day -21 and Day -1 to determine eligibility in the study. Those participants that meet the eligibility criteria will be admitted to the study site on the day prior to dosing (Day -1). Participants will receive a single dose of investigational product via IV infusion on Day 1. The first cohort will include the initial dosing of a sentinel group. The remaining participants in Cohort 1 will be dosed if, in the opinion of the investigator or delegate, there are no significant safety concerns identified in the sentinel participants within the first 24 hours after administration of the dose. Participants will be confined to the study site from Day -1 to Day 2 (24 hours post dose) and then required to return to the study site on Day 5 for a final follow up visit. Safety and PK assessments will be performed at selected time points throughout the study. Part 2 is designed as a Multiple Ascending Dose (MAD) escalation study with 3 cohorts. The MAD arm of the study will commence in parallel with Cohort 6 of Part 1 following completion and review of safety and PK findings for Cohorts 1, 2, 3, 4, and 5 in Part 1. Participants will undertake a screening visit between Day -21 and Day -1 to determine eligibility in the study. Those participants that meet the eligibility criteria will be admitted to the study site on the day prior to dosing (Day -1). Participants will be randomly assigned to receive 1 of 3 proposed doses of investigational product via IV infusion every day for 7 days.Participants will be confined to the study site from Day -1 to Day 8 (24 hours post the final dose on Day 7) and then return to the study site on Day 12 for a final follow up visit. Safety and PK assessments will be performed at selected time points throughout the study.
Interventions
DRUGRJX
RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
DRUGPlacebo
Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
Sponsors
ICON plc
ERT: Clinical Trial Technology Solutions
Reven Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male and female participants aged 18 to 50 years inclusive (Cohort 1 to Cohort 5) or 51 to 70 years inclusive (Cohort 6 only),at the time of screening; 2. Have a body mass index of 18 kg/m2 to 35 kg/m2, inclusive, at screening. In addition, weight cannot exceed 132 kg; 3. Have negative screening assessment for viral hepatitis (hepatitis B or hepatitis C) and human immunodeficiency virus; 4. Have negative routine urine drug screen and negative alcohol breath test at screening and Day -1; 5. A female participant is eligible to participate if she is not pregnant,not breastfeeding, and at least 1 of the following conditions applies: 1. Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); 2. Of childbearing potential and agrees to use 2 highly effective methods of contraception consistently during the treatment period and for at least 60 days after the last dose of investigational product; 6. A male participant with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for at least 60 days after the last dose of investigational product and refrains from donating sperm during this period; 7. Clinical laboratory test results within normal reference range for the population or investigator site, or any results that are judged to be not clinically significant by the investigator; 8. Venous access sufficient to allow for blood sampling per the protocol; 9. Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures; 10. Given written informed consent prior to any study procedures being performed
Exclusion criteria
1. Have a history of clinically relevant cardiovascular disease, cancer, respiratory, hepatic, renal, gastrointestinal, endocrine (diabetes), hematological, or neurological disorders. Cohort 6 only - elderly participants with well controlled hypercholesterolemia on a stable dose of statin therapy or well controlled hypertension on a stable dose of antihypertensive medication(s), excluding diuretics, are allowed in Cohort 6 per the clinical judgment of the investigator. 2. Have impaired renal function (defined as estimated glomerular filtration rate \<90 cc/min/1.73m2 Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) creatinine equation at screening); 3. Have a hsCRP above 1.25 × upper limit of normal; 4. Have a clinically significant abnormality in the 12-lead electrocardiogram (ECG) or prolongation of corrected QT interval by Fredericia (QTcF) \>440 ms in males and \>450 ms in females; 5. Have a supine systolic blood pressure (BP) greater than 140 mm Hg or a diastolic BP greater than 90 mm Hg. Up to 2 additional measurements may be undertaken after an appropriate resting interval at screening to confirm eligibility; 6. Are currently enrolled in a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study; 7. Have received an investigational product within the last 3 months; 8. Have suspected allergies to RJX, related compounds, or any components of the formulation, or history of significant atopy; 9. Regularly use known drugs of abuse and/or show positive findings on drug screening or Day -1; 10. Are women who are pregnant, intend to become pregnant, or are lactating; 11. Participants will be excluded for using any of the following medication: * aspirin, multivitamins/vitamins or mineral preparations within 14 days prior to investigational product administration or 24 hours post the last infusion; * prescription, herbal or over the counter medications within 14 days of investigational product administration, with the exception of: * simple analgesics such as paracetamol, excluding aspirin * oral non-steroidal anti-inflammatory drugs * thyroid treatment, estrogen replacement therapy * hormonal contraception * Statins and anti-hypertensives are permitted for elderly participants in Cohort 6 (Part 1) - see inclusion criteria #1 12. Have donated blood of more than 500 mL within 4 weeks prior to study enrollment; 13. Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females) or are unwilling to stop alcohol consumption for 24 hours prior to study site admission (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits). Participants must have a of negative alcohol breath test at Day -1 and no evidence of alcohol abuse in the previous 12 months, defined as \> 21 weekly units for males up to age 65 and \> 14 weekly units for males over 65 and females; 14. Have smoked cigarettes in the last 90 days (including occasional smokers who have smoked more than 5 cigarettes per month within the last 90 days); 15. In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study; 16. Are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted; 17. Are Reven employees or employees of third-party organizations involved with the study who require exclusion of their employees.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment-related Adverse Events (TEAE) Reporting of RJX | Up to Day 5 for Part 1 and Up to Day 12 for Part 2 | Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03 |
| Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | Up to Day 2 for Part 1 and Up to Day 8 for Part 2 | Number of participants with abnormal and clinically significant findings based on ECG. |
| Safety and Tolerability of RJX as Assessed by Neurological Examinations. | Up to Day 5 for Part 1 and Up to Day 12 for Part 2 | Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments. |
Countries
United States
Participant flow
Recruitment details
Participants received either Rejuveinix (RJX) or saline placebo.
Participants by arm
| Arm | Count |
|---|---|
| Part 1; Cohort 1; RJX or Placebo Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX or matching placebo on Day 1. | 8 |
| Part 1; Cohort 2; RJX or Placebo Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX or matching placebo on Day 1. | 8 |
| Part 1; Cohort 3; RJX or Placebo Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX or matching placebo on Day 1. | 8 |
| Part 1; Cohort 4; RJX or Placebo Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX or matching placebo on Day 1. | 8 |
| Part 1; Cohort 5; RJX or Placebo Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX or matching placebo on Day 1. | 8 |
| Part 1; Cohort 6; RJX or Placebo Participants in Part 1; Cohort 6 received a single dose of 0.500 mL/kg RJX or matching placebo on Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 51-70 inclusive. | 12 |
| Part 2; Cohort 1; RJX or Placebo Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX or matching placebo every day for 7 days. | 8 |
| Part 2; Cohort 2; RJX or Placebo Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX or matching placebo every day for 7 days. | 8 |
| Part 2; Cohort 3; RJX or Placebo Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX or matching placebo every day for 7 days. | 8 |
| Total | 76 |
Baseline characteristics
| Characteristic | Total | Part 1; Cohort 2; RJX or Placebo | Part 1; Cohort 3; RJX or Placebo | Part 1; Cohort 1; RJX or Placebo | Part 1; Cohort 4; RJX or Placebo | Part 1; Cohort 5; RJX or Placebo | Part 1; Cohort 6; RJX or Placebo | Part 2; Cohort 1; RJX or Placebo | Part 2; Cohort 2; RJX or Placebo | Part 2; Cohort 3; RJX or Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 76 Participants | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 12 Participants | 8 Participants | 8 Participants | 8 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 28 Participants | 2 Participants | 3 Participants | 2 Participants | 5 Participants | 3 Participants | 4 Participants | 2 Participants | 0 Participants | 7 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 47 Participants | 6 Participants | 5 Participants | 6 Participants | 3 Participants | 5 Participants | 8 Participants | 5 Participants | 8 Participants | 1 Participants |
| Region of Enrollment United States | 76 participants | 8 participants | 8 participants | 8 participants | 8 participants | 8 participants | 12 participants | 8 participants | 8 participants | 8 participants |
| Sex: Female, Male Female | 39 Participants | 4 Participants | 6 Participants | 5 Participants | 5 Participants | 3 Participants | 7 Participants | 0 Participants | 4 Participants | 5 Participants |
| Sex: Female, Male Male | 37 Participants | 4 Participants | 2 Participants | 3 Participants | 3 Participants | 5 Participants | 5 Participants | 8 Participants | 4 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 9 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 2 / 13 | 1 / 6 | 2 / 6 | 0 / 6 | 3 / 6 | 2 / 6 | 0 / 9 | 1 / 6 | 1 / 6 | 3 / 6 | 3 / 6 |
| serious Total, serious adverse events | 0 / 13 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 9 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 |
Outcome results
Primary
Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).
Number of participants with abnormal and clinically significant findings based on ECG.
Time frame: Up to Day 2 for Part 1 and Up to Day 8 for Part 2
Population: Counts of 12-lead safety ECG interpretations across Intent to Treat (ITT) population showed no notable changes when compared to baseline for either study part.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1; Placebo | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 1; Cohort 1; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 1; Cohort 2; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 1; Cohort 3; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 1; Cohort 4; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 1; Cohort 5; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 1; Cohort 6; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 2; Placebo | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 2; Cohort 1; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 2; Cohort 2; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
| Part 2; Cohort 3; RJX | Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs). | 0 Participants |
Primary
Safety and Tolerability of RJX as Assessed by Neurological Examinations.
Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments.
Time frame: Up to Day 5 for Part 1 and Up to Day 12 for Part 2
Population: Analysis based on Intent to Treat (ITT) population across Part 1 and Part 2, all cohorts. Only 1 subject, one incidence, for the study; presented on Day 12, Principal Investigator considered clinically significant and a mild TEAE considered unlikely related to RJX.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1; Placebo | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 1; Cohort 1; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 1; Cohort 2; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 1; Cohort 3; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 1; Cohort 4; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 1; Cohort 5; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 1; Cohort 6; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 2; Placebo | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 2; Cohort 1; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
| Part 2; Cohort 2; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 1 Participants |
| Part 2; Cohort 3; RJX | Safety and Tolerability of RJX as Assessed by Neurological Examinations. | 0 Participants |
Primary
Treatment-related Adverse Events (TEAE) Reporting of RJX
Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03
Time frame: Up to Day 5 for Part 1 and Up to Day 12 for Part 2
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 11 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 0 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 13 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 13 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 2 Participants |
| Part 1; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 13 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 5 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 1 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 1 Participants |
| Part 1; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 5 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 5 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 4 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 2 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 1 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 1 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 4 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 2 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 5 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 2 Participants |
| Part 1; Cohort 4; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 4 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 2 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 5 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 2 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 4 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 4 Participants |
| Part 1; Cohort 5; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 1 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 9 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 9 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 9 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 0 Participants |
| Part 1; Cohort 6; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 9 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 1 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 1 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 1 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 5 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 5 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 2; Placebo | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 5 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 1 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 5 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 6 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 1; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 6 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 6 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 3 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 4 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 3 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 2 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 2; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | Without TEAE | 4 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | Without TEAE | 5 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Moderate TEAE | With TEAE | 1 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | With TEAE | 0 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Mild TEAE | With TEAE | 2 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Related TEAE | Without TEAE | 6 Participants |
| Part 2; Cohort 3; RJX | Treatment-related Adverse Events (TEAE) Reporting of RJX | Severe TEAE | Without TEAE | 6 Participants |